| Anna Janulewicz, AA | |
|
4025 N 92nd St, Wauwatosa, WI 53222-1613 | |
| (414) 358-5431 | |
| Not Available |
| Full Name | Anna Janulewicz |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 12 Years |
| Location | 4025 N 92nd St, Wauwatosa, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003167008 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic Hospital | Weston, FL | Hospital |
| Memorial Regional Hospital | Hollywood, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bethesda Anesthesia Associates, Inc. | 3971670795 | 19 |
| Cleveland Clinic Florida A Nonprofit Corporation | 7911807128 | 618 |
| Sheridan Healthcorp Inc | 3173429693 | 866 |
News Archive
Vitamins, minerals, herbs and other dietary supplements are widely available in supermarkets and drug stores across the nation without a prescription, so it's no surprise that nearly half of all Americans take them.
Pregnant women who take extra choline supplements may mitigate the negative impact that viral respiratory infections, including COVID-19, can have on their babies, according to a new study from researchers in the Departments of Psychiatry and Obstetrics and Gynecology at the University of Colorado Anschutz Medical Campus.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.
Obamacare is starting to resemble a patient bleeding from self-inflicted wounds. A month after launch, the online health exchanges where individuals are supposed to shop for insurance remain slow or unusable, except in states that opted to run their own marketplaces and did a more competent job than the administration. As if that weren't trouble enough, critics are justifiably mocking President Obama for his repeated, untrue promise that if people liked their health plans, they could keep them. Oops. Hundreds of thousands of people are getting termination notices for plans that don't meet the strict new requirements of the Affordable Care Act. Presumably, not all those people disliked their plans (11/3).
› Verified 1 days ago
| Entity Name | Sheridan Healthcorp Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629781711 PECOS PAC ID: 3173429693 Enrollment ID: O20031208000355 |
News Archive
Vitamins, minerals, herbs and other dietary supplements are widely available in supermarkets and drug stores across the nation without a prescription, so it's no surprise that nearly half of all Americans take them.
Pregnant women who take extra choline supplements may mitigate the negative impact that viral respiratory infections, including COVID-19, can have on their babies, according to a new study from researchers in the Departments of Psychiatry and Obstetrics and Gynecology at the University of Colorado Anschutz Medical Campus.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.
Obamacare is starting to resemble a patient bleeding from self-inflicted wounds. A month after launch, the online health exchanges where individuals are supposed to shop for insurance remain slow or unusable, except in states that opted to run their own marketplaces and did a more competent job than the administration. As if that weren't trouble enough, critics are justifiably mocking President Obama for his repeated, untrue promise that if people liked their health plans, they could keep them. Oops. Hundreds of thousands of people are getting termination notices for plans that don't meet the strict new requirements of the Affordable Care Act. Presumably, not all those people disliked their plans (11/3).
› Verified 1 days ago
| Entity Name | Cleveland Clinic Florida A Nonprofit Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215989298 PECOS PAC ID: 7911807128 Enrollment ID: O20040113000394 |
News Archive
Vitamins, minerals, herbs and other dietary supplements are widely available in supermarkets and drug stores across the nation without a prescription, so it's no surprise that nearly half of all Americans take them.
Pregnant women who take extra choline supplements may mitigate the negative impact that viral respiratory infections, including COVID-19, can have on their babies, according to a new study from researchers in the Departments of Psychiatry and Obstetrics and Gynecology at the University of Colorado Anschutz Medical Campus.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.
Obamacare is starting to resemble a patient bleeding from self-inflicted wounds. A month after launch, the online health exchanges where individuals are supposed to shop for insurance remain slow or unusable, except in states that opted to run their own marketplaces and did a more competent job than the administration. As if that weren't trouble enough, critics are justifiably mocking President Obama for his repeated, untrue promise that if people liked their health plans, they could keep them. Oops. Hundreds of thousands of people are getting termination notices for plans that don't meet the strict new requirements of the Affordable Care Act. Presumably, not all those people disliked their plans (11/3).
› Verified 1 days ago
| Entity Name | Bethesda Anesthesia Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801054473 PECOS PAC ID: 3971670795 Enrollment ID: O20080920000183 |
News Archive
Vitamins, minerals, herbs and other dietary supplements are widely available in supermarkets and drug stores across the nation without a prescription, so it's no surprise that nearly half of all Americans take them.
Pregnant women who take extra choline supplements may mitigate the negative impact that viral respiratory infections, including COVID-19, can have on their babies, according to a new study from researchers in the Departments of Psychiatry and Obstetrics and Gynecology at the University of Colorado Anschutz Medical Campus.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.
Obamacare is starting to resemble a patient bleeding from self-inflicted wounds. A month after launch, the online health exchanges where individuals are supposed to shop for insurance remain slow or unusable, except in states that opted to run their own marketplaces and did a more competent job than the administration. As if that weren't trouble enough, critics are justifiably mocking President Obama for his repeated, untrue promise that if people liked their health plans, they could keep them. Oops. Hundreds of thousands of people are getting termination notices for plans that don't meet the strict new requirements of the Affordable Care Act. Presumably, not all those people disliked their plans (11/3).
› Verified 1 days ago
| Entity Name | American Anesthesiology Services Of Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508318387 PECOS PAC ID: 1850674540 Enrollment ID: O20170202001989 |
News Archive
Vitamins, minerals, herbs and other dietary supplements are widely available in supermarkets and drug stores across the nation without a prescription, so it's no surprise that nearly half of all Americans take them.
Pregnant women who take extra choline supplements may mitigate the negative impact that viral respiratory infections, including COVID-19, can have on their babies, according to a new study from researchers in the Departments of Psychiatry and Obstetrics and Gynecology at the University of Colorado Anschutz Medical Campus.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.
Obamacare is starting to resemble a patient bleeding from self-inflicted wounds. A month after launch, the online health exchanges where individuals are supposed to shop for insurance remain slow or unusable, except in states that opted to run their own marketplaces and did a more competent job than the administration. As if that weren't trouble enough, critics are justifiably mocking President Obama for his repeated, untrue promise that if people liked their health plans, they could keep them. Oops. Hundreds of thousands of people are getting termination notices for plans that don't meet the strict new requirements of the Affordable Care Act. Presumably, not all those people disliked their plans (11/3).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna Janulewicz, AA 4025 N 92nd St, Wauwatosa, WI 53222-1613 Ph: (414) 358-5431 | Anna Janulewicz, AA 4025 N 92nd St, Wauwatosa, WI 53222-1613 Ph: (414) 358-5431 |
News Archive
Vitamins, minerals, herbs and other dietary supplements are widely available in supermarkets and drug stores across the nation without a prescription, so it's no surprise that nearly half of all Americans take them.
Pregnant women who take extra choline supplements may mitigate the negative impact that viral respiratory infections, including COVID-19, can have on their babies, according to a new study from researchers in the Departments of Psychiatry and Obstetrics and Gynecology at the University of Colorado Anschutz Medical Campus.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.
Obamacare is starting to resemble a patient bleeding from self-inflicted wounds. A month after launch, the online health exchanges where individuals are supposed to shop for insurance remain slow or unusable, except in states that opted to run their own marketplaces and did a more competent job than the administration. As if that weren't trouble enough, critics are justifiably mocking President Obama for his repeated, untrue promise that if people liked their health plans, they could keep them. Oops. Hundreds of thousands of people are getting termination notices for plans that don't meet the strict new requirements of the Affordable Care Act. Presumably, not all those people disliked their plans (11/3).
› Verified 1 days ago
Mr. Timothy Klusman, A.A. Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 Fax: 414-358-5421 | |
Kojo Bempong, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: Ahcmg Anesthesiology, 4025 North 92nd Street, Wauwatosa, WI 53022 Phone: 414-358-5431 | |
Erin E Taylor, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 | |
Brian A White, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 | |
John G Rippy, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 4025 N 92nd St, Wauwatosa, WI 53222 Phone: 414-358-5431 |